These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25172870)

  • 1. Clinicohematologic Profile of Patients With Factor VIII Inhibitors: A Case Series.
    Singh N; Mishra P; Tyagi S; Pati HP; Mahapatra M; Seth T; Saxena R
    Clin Appl Thromb Hemost; 2015 Apr; 21(3):246-50. PubMed ID: 25172870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response to FVIII in hemophilia A: an overview of risk factors.
    Ghosh K; Shetty S
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):58-66. PubMed ID: 19148784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired hemophilia A in chronic lymphocytic leukemia: A case report.
    Karakuş V; Kaya E; Dere Y; Kurtoğlu E
    Transfus Apher Sci; 2019 Aug; 58(4):447-448. PubMed ID: 31320278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening.
    Miller CH; Rice AS; Boylan B; Payne AB; Kelly FM; Escobar MA; Gill J; Leissinger C; Soucie JM;
    Am J Hematol; 2015 Oct; 90(10):871-6. PubMed ID: 26147783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
    Batorova A; Jankovicova D; Morongova A; Bubanska E; Prigancova T; Horakova J; Machyniakova M; Cervenka J; Chandoga J; Böhmer D; Mistrik M
    Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A cross-sectional survey of coagulation factor VIII inhibitor in children with hemophilia A].
    Wei Q; Li G; Tang L; Chen Z; Zhen Y; Wu X; Zhang N; Zhang J; Yu G; Wu R
    Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):99-102. PubMed ID: 24739719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Leebeek FWG; Escuriola-Ettingshausen C; Hermans C; Keenan R; Astermark J; Male C; Peerlinck K; le Cessie S; van der Bom JG; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1422-1429. PubMed ID: 28440011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors: our greatest challenge. Can we minimize the incidence?
    Kruse-Jarres R
    Haemophilia; 2013 Jan; 19 Suppl 1():2-7. PubMed ID: 23278993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Oldenburg J; Cnossen M; Liesner R; Morfini M; Castaman G; McRae S; van der Bom JG; Fijnvandraat K;
    Br J Haematol; 2020 Jun; 189(6):1182-1191. PubMed ID: 32201943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
    Mannucci PM; Franchini M
    Blood Transfus; 2017 Jul; 15(4):365-368. PubMed ID: 27483484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemostatic treatment using factor VIII concentrates for neutralizing high-responding inhibitors prior to CVAD insertion for immune-tolerance induction therapy.
    Shibata M; Nakagawa T; Akioka S; Giddings JC; Kanehiro H; Matsumoto T; Ogiwara K; Yada K; Shima M
    Clin Appl Thromb Hemost; 2012; 18(1):66-71. PubMed ID: 21733937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FVIII, CD4, and liaisons dangereuses.
    Ragni MV
    Blood; 2011 Jun; 117(23):6060-1. PubMed ID: 21659552
    [No Abstract]   [Full Text] [Related]  

  • 13. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
    Gouw SC; van den Berg HM; Fischer K; Auerswald G; Carcao M; Chalmers E; Chambost H; Kurnik K; Liesner R; Petrini P; Platokouki H; Altisent C; Oldenburg J; Nolan B; Garrido RP; Mancuso ME; Rafowicz A; Williams M; Clausen N; Middelburg RA; Ljung R; van der Bom JG;
    Blood; 2013 May; 121(20):4046-55. PubMed ID: 23553768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study.
    Kempton CL; Payne AB
    Blood Adv; 2018 Jul; 2(14):1750-1755. PubMed ID: 30037801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired factor VIII inhibitors: pathophysiology and treatment.
    Ma AD; Carrizosa D
    Hematology Am Soc Hematol Educ Program; 2006; ():432-7. PubMed ID: 17124095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.
    Wootla B; Dasgupta S; Dimitrov JD; Bayry J; Lévesque H; Borg JY; Borel-Derlon A; Rao DN; Friboulet A; Kaveri SV; Lacroix-Desmazes S
    J Immunol; 2008 Jun; 180(11):7714-20. PubMed ID: 18490775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Klukowska A; Komrska V; Jansen M; Laguna P
    Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone.
    Holstein K; Marx G; Lentz B; Bokemeyer C; Langer F
    Hamostaseologie; 2012; 32 Suppl 1():S48-51. PubMed ID: 22960877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.